Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 ...
Clene Inc. secured an in-person meeting with senior FDA leadership to discuss CNM-Au8 for ALS, presenting biomarker, clinical endpoint, and survival data. The company has over 700 patient-years of safety data for CNM-Au8 with no significant concerns.
Reference News
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 ...
Clene Inc. secured an in-person meeting with senior FDA leadership to discuss CNM-Au8 for ALS, presenting biomarker, clinical endpoint, and survival data. The company has over 700 patient-years of safety data for CNM-Au8 with no significant concerns.